<?xml version="1.0" encoding="UTF-8"?>
<fig id="fig1" position="float">
 <label>Figure 1</label>
 <caption>
  <p>Niclosamide has great potential in being repurposed to treat a variety of viral infections, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), Zika virus (ZIKV), Japanese encephalitis virus (JEV), hepatitis C virus (HCV), Ebola virus (EBOV), human rhinoviruses (HRVs), Chikungunya virus (CHIKV), human adenovirus (HAdV), and Epsteinâ€“Barr virus (EBV). We envision that this broad spectrum of antival activities may offer the therapeutic potential to be extended to combat fast-spreading coronavirus disease 2019 (COVID-19), given its inexpensive and low 
   <italic>in vivo</italic> toxicity profile as an FDA-approved drug in clinical use.
  </p>
 </caption>
 <graphic xlink:href="id0c00052_0001" id="gr1" position="float" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
